Introduction
============

The potential overlap between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy (ARVC) has been subject of heated debate (Martini et al., [@B47]; Pérez Riera et al., [@B61]). Contested in this debate are the myocardial condition and thereby the arrhythmogenic mechanism underlying the Brugada syndrome. This review will described the clinical features and explore the overlap of these features between these syndromes.

Arrhythmogenic Right Ventricular Cardiomyopathy
===============================================

Marcus et al. ([@B45]) published a case series that for the first time captured the clinical profile of ARVC. In 24 patients, they described the fibro-fatty replacement, the ventricular tachyarrhythmias, and premature ventricular complexes with left bundle branch block morphology, the repolarization abnormalities in the form of inversed T-waves in the right precordial leads, delayed activation on standard or signal averaged ECGs, the morphological features of increased dimensions and wall motion abnormalities of the right ventricle and the familial occurrence of this disorder. The causative mechanism was unknown and was speculated to lie in the development of the right ventricle hence it was termed "arrhythmogenic right ventricular dysplasia" (Marcus et al., [@B45]).

Since, our understanding of the causative mechanism of ARVC has progressed substantially. An important step was made by the association of ARVC with mutations in the genes encoding the desmosomal proteins plakoglobin (McKoy et al., [@B50]), desmoplakin (Rampazzo et al., [@B70]), plakophilin-2 (Gerull et al., [@B27]), desmoglein-2 (Pilichou et al., [@B64]), and desmocollin-2 (Heuser et al., [@B29]). These proteins are located at the intercalated disk in adhering junctions, which in the heart contain both desmosomal and fascia adherens components, and provide mechanical strength to the cell--cell junction (Borrmann et al., [@B8]; Franke et al., [@B24]). Mechanical overload of the cell--cell junction is considered to trigger the pathophysiological myocardial changes in ARVC (Delmar and McKenna, [@B21]). Mutations in these genes can be identified in ∼40% of ARVC patients (Sen-Chowdhry et al., [@B74]).

The concept of mechanical overload of the cell--cell junction has been substantiated further by mouse models of ARVC (Garcia-Gras et al., [@B26]; Kirchhof et al., [@B39]; Pilichou et al., [@B65]). Consistent with the concept of mechanical overload of the cell--cell junctions, the development of cardiomyopathy in mouse models can be influenced by altering the mechanical load on the heart: endurance training accelerates (Kirchhof et al., [@B39]) and pharmacological therapy that lowers the hemodynamic load slows the development of the ARVC phenotype in heterozygous plakoglobin deficient mice (Fabritz et al., [@B23]). Indeed, ARVC patients engaged in endurance training appear to have a more severe ARVC phenotype than those that are not (Sen-Chowdhry et al., [@B75]).

The mutations associated with ARVC have been incorporated in the revised diagnostic Task Force Criteria as published in 2010 (Marcus et al., [@B46]). These diagnostic criteria are divided in six categories: depolarization/conduction abnormalities, repolarization abnormalities, ventricular arrhythmias, right ventricular structural or functional characteristics as demonstrated by imaging techniques, histological criteria, and familial occurrence of ARVC or presence of mutations associated or probably associated with ARVC (Table [1](#T1){ref-type="table"}). In each category, a major or minor criteria can be scored. A definite diagnosis of ARVC is made in the presence of two major, one major and two minor or four minor criteria. The presence of one major and one minor or three minor criteria is classified as "borderline" and one major or two minor criteria as "possible" diagnosis of ARVC.

###### 

**Revised task force criteria for arrhythmogenic right ventricular cardiomyopathy**.

  -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  **DEPOLARIZATION/CONDUCTION ABNORMALITIES**                                
  Major                                                                      Epsilon wave (V1, V2, or V3)
  Minor                                                                      Signal averaged ECG in the absence of QRSD \>110 ms
                                                                                  fQRS duration \>114 ms or
                                                                                  Duration of terminal QRS \<40 μV ≥38 ms or
                                                                                  Root-mean-square voltage of terminal 40 ms ≤20 μV
                                                                             Terminal activation delay ≥55 ms
  **REPOLARIZATION ABNORMALITIES (IN PATIENTS \>14 YEARS OF AGE)**           
  Major                                                                      Negative T-wave in V1, V2, and V3 (without complete RBBB)
  Minor                                                                      Negative T-wave in V1 and V2 or in V4, V5, or V6 (without complete RBBB)
                                                                             Negative T-wave in V1, V2, V3, and V4 with complete RBBB
  **VENTRICULAR ARRHYTHMIAS**                                                
  Major                                                                      Non-sustained or sustained VT with LBBB pattern with superior axis
  Minor                                                                      Non-sustained or sustained VT with LBBB pattern with inferior or unknown axis
                                                                             \>500 Premature ventricular complexes/24 h
  **IMAGING TECHNIQUES**                                                     
  Major                                                                      2D Echocardiography
                                                                             Regional RV akinesia, dyskinesia, or aneurysm and
                                                                                  PLAX RVOT \>32 mm (or PLAX RVOT \>19 mm/m^2^) or
                                                                                  PSAX RVOT \>36 mm (or PSAX RVOT \>21 mm/m^2^) or
                                                                                  Fractional area change \<33%
                                                                             MRI
                                                                             Regional RV akinesia, dyskinesia, or dyssynchronous RV contraction and
                                                                                  Ratio of RVEDV to BSA \>110 ml/m^2^ (male) or \>100 ml/m^2^ (female) or
                                                                                  RV ejection faction \<40%
                                                                             RV angiography
                                                                             Regional RV akinesia, dyskinesia, or aneurysm
  Minor                                                                      2D Echocardiography
                                                                             Regional RV akinesia or dyskinesia and
                                                                                  PLAX RVOT ≥29 to \<32 mm (or PLAX RVOT ≥16 to \<19 mm/m^2^) or
                                                                                  PLAX RVOT ≥32 to \<36 mm (or PLAX RVOT ≥18 to \<21 mm/m^2^) or
                                                                                  Fractional area change ≥33 to \<40%
                                                                             MRI
                                                                             Regional RV akinesia, dyskinesia, or dyssynchronous RV contraction and
                                                                                  Ratio of RVEDV to BSA ≥100 to \<110 ml/m^2^ (male) or ≥90 to \>100 ml/m^2^ (female) or
                                                                                  RV ejection faction ≥40 to \<45%
  **HISTOLOGY (ENDOMYOCARDIAL BIOPSY FROM RVFW WITH FIBROUS REPLACEMENT)**   
  Major                                                                      Residual myocytes \<60% on morphometric analysis (or \<50% estimated)
  Minor                                                                      Residual myocytes 60--75% on morphometric analysis (or 50--65% estimated)
  **FAMILY HISTORY**                                                         
  Major                                                                      First degree relative with ARVC according to current task force criteria
                                                                             First degree relative with pathologically confirmed ARVC (surgery or atopsy)
                                                                             Pathogenic mutation categorized as associated or probably associated with ARVC
  Minor                                                                      First degree relative with ARVC undetermined whether diagnosis meets current task force criteria
                                                                             First degree relative with sudden death \<35 years of age suspected to be related to ARVC
                                                                             Second degree relative with ARVC according to current task force criteria
  -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------

*Adapted from Marcus et al. ([@B46]). RBBB, right bundle branch block; VT, ventricular tachycardia; LBBB, left bundle branch block; PLAX, parasternal long-axis view; RVOT, right ventricular outflow tract; PSAX, parasternal short-axis view; RVEDV, right ventricular end diastolic volume; BSA, body surface area; RV, right ventricle; ARVC, arrhythmogenic right ventricular cardiomyopathy*.

The Brugada Syndrome
====================

Brugada and Brugada ([@B11]) introduced a new clinical entity characterized by right precordial ST-segment elevation followed by a negative T-wave and sudden cardiac arrest by ventricular fibrillation in otherwise healthy individuals. No underlying cause of the arrhythmias in the form of electrolyte disturbances, coronary, or structural heart disease could be identified in these now called Brugada syndrome patients.

The characteristic electrocardiographic feature (Brugada ECG pattern) is dynamic and can even disappear temporarily (Brugada and Brugada, [@B10]). Prior to the initiation of ventricular fibrillation however, the Brugada ECG pattern reappears in these patients (Kasanuki et al., [@B37]). The Brugada ECG pattern is most pronounced at night or at rest (Mizumaki et al., [@B52]), during febrile illness (Amin et al., [@B3]), and after consumption of a copious meal (Ikeda et al., [@B34]) which also are known triggers of ventricular tachyarrhythmias and sudden death in Brugada syndrome patients (Matsuo et al., [@B49]; Ikeda et al., [@B34]; Amin et al., [@B3]; Takigawa et al., [@B78]). Furthermore, pharmacological agents have been demonstrated to modulate the Brugada ECG pattern. Sodium channel blockers are known to augment or provoke the Brugada ECG pattern (Miyazaki et al., [@B51]). Other drugs can ameliorate the Brugada ECG pattern such as isoproterenol (Miyazaki et al., [@B51]) and quinidine (Alings et al., [@B2]) and have been used to prevent arrhythmias in observational studies and case reports (Tanaka et al., [@B79]; Belhassen et al., [@B7]). These findings suggested the Brugada syndrome to be a functional electrical cardiac disorder (Ackerman et al., [@B1]).

Thus far, mutations in 11 genes have been associated with the Brugada syndrome. Most of these mutations reduce the cardiac sodium current (*I*~Na~) and are located in *SCN5A* (Chen et al., [@B15]), the gene encoding the cardiac sodium channel, its β-subunits *SCN1B* (Watanabe et al., [@B81]) and *SCN3B* (Hu et al., [@B33]) or in *GPD1L* (London et al., [@B44]) and *MOG1* (Kattygnarath et al., [@B38]) which are thought to impair trafficking of the cardiac sodium channel to the cell membrane. Other mutations associated with the Brugada syndrome reduce the L-type calcium current (*I*~CaL~) and are located in *CACNA1C*, *CACNB2b* (Antzelevitch et al., [@B5]) and *CACNA2D1* (Burashnikov et al., [@B12]) which encode the α1-, β2b-, and α2δ-subunit of the L-type calcium channel. Lastly, mutations in *KCNE3* which encodes MiRP2, a β-subunit of several potassium channels (Delpon et al., [@B22]), and in *KCNJ8* encoding the ATP-sensitive potassium channel (Barajas-Martínez et al., [@B6]) have been associated with the Brugada syndrome. These mutations have been suggested to increase repolarizing currents activated early during the action potential (Delpon et al., [@B22]; Barajas-Martínez et al., [@B6]).

The role these mutations play in the Brugada syndrome is subject of debate. The most common of these mutations appear to be located in *SCN5A* which can be identified in ∼25% of Brugada syndrome patients (Probst et al., [@B68]). Even in these patients, the role of loss-of-function mutations in *SCN5A* appears to be more complex than that of a dominant mutation with incomplete penetrance. In families affected by the Brugada syndrome in which the index patient carried a mutation in *SCN5A*, a significant number of Brugada syndrome patients (∼1 in 8) does not carry the mutation in *SCN5A* (Probst et al., [@B69]; Santos et al., [@B72]).

The mutations associated with Brugada syndrome have not been incorporated in the diagnostic criteria for Brugada syndrome as put forward in the 2005 consensus report (Table [2](#T2){ref-type="table"}; Antzelevitch et al., [@B4]).

###### 

**Diagnostic criteria of Brugada syndrome**.

  -----------------------------------------------------------------------------------------------------
  Brugada ECG pattern spontaneous or drug-induced \>1 precordial lead and

  (Signs of) ventricular tachyarrhythmias in the patient or his/her family\
       Documented ventricular fibrillation or polymorphic VT or\
       Syncope or nocturnal agonal breathing or\
       Inducibility of VT/VF with programmed electrical stimulation or\
       Family history of sudden cardiac death \<45 years of age or\
       Family history of the Brugada ECG pattern without

  Confounding factors and factors accounting for the Brugada ECG pattern or syncopes

       Electrocardiographic phenomena that can mimic the Brugada ECG pattern or

       Electrolyte disturbances or hypothermia or

       Conditions with ST-segment elevation: pericarditis, myocardial ischemia, pulmonary embolism or

       Structural heart disease such as ARVC or

       Miscellaneous
  -----------------------------------------------------------------------------------------------------

*Adapted from Antzelevitch et al. ([@B4]). VT, ventricular tachycardia; VF, ventricular fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy*.

Overlapping Features between Brugada Syndrome and ARVC
======================================================

As apparent from the diagnostic criteria, Brugada syndrome and ARVC are distinct clinical entities with a different scope of clinical features. Nonetheless, a remarkable number of publications have shown that features of both syndromes occur in conjunction in some patients.

Brugada Syndrome Features in ARVC Patients
==========================================

Prior to the introduction of the Brugada syndrome, Martini et al. ([@B48]) presented a patient with right precordial ST-segment elevation and idiopathic ventricular fibrillation. One patient demonstrated what was later to be called the Brugada ECG pattern. Careful clinical re-evaluation demonstrated enlargement of the right ventricular outflow tract and right ventricular wall motion abnormalities. This caused the authors to conclude that a concealed form of ARVC was present in this patient. Since, more histological findings consistent with ARVC have been demonstrated at autopsy series of patients with the Brugada ECG (Corrado et al., [@B19], [@B18]; Tada et al., [@B77]). The largest series was presented by Corrado et al. ([@B18]) and consisted of 13 young sudden cardiac death victims with a Brugada ECG pattern on their last recorded ECG. Of these patients, 12 demonstrated structural heart disease consistent with ARVC at autopsy. Similar to Brugada syndrome patients (Matsuo et al., [@B49]), most of these patients died at night or at rest (Tada et al., [@B77]; Corrado et al., [@B18]). Furthermore, polymorphic VTs as observed in the Brugada syndrome were recorded in some these ARVC patients (Corrado et al., [@B18]).

Secondly, sodium channel blockers can induce the Brugada ECG pattern ∼1 in 6 patients previously diagnosed with ARVC (Peters et al., [@B63]; Peters, [@B62]). These data indicate the Brugada ECG pattern, the associated ventricular arrhythmias are present and can be modulated by *I*~Na~ in some ARVC patients.

ARVC Features in Brugada Syndrome Patients
==========================================

Diagnostic ARVC criteria (Marcus et al., [@B46]) have vice-versa been demonstrated in Brugada syndrome patients. Thus far, the diagnostic criteria of ARVC have been validated to distinguish ARVC from idiopathic right ventricular outflow tract tachycardias (Nasir et al., [@B56]; Cox et al., [@B20]) but not from Brugada syndrome.

Ventricular activation abnormalities in the Brugada syndrome are well known (Postema et al., [@B66]). Thus far, Letsas et al. ([@B43]) published the only paper that described the presence of electrocardiographic ARVC criteria in Brugada syndrome patients in the absence of sodium channel blockers. Epsilon waves appear to be rare in Brugada syndrome patients and were found in 2 of 47 patients. Other conduction abnormalities appear to be more common with 40% demonstrating terminal activation delay \>55 ms (Letsas et al., [@B43]). Late potential on signal averaged ECG also appear to be common in Brugada syndrome patients and could be identified by Ikeda et al. ([@B35]) in the majority of patients despite using more restrictive cut-off values than the revised Task Force Criteria of ARVC (≥2 LP criteria vs ≥1).

The monomorphic VTs with left bundle branch block are rare in Brugada syndrome patients but have been described in case reports (Viskin and Belhassen, [@B80]). Premature ventricular complexes are rare in Brugada syndrome patients (Krittayaphong et al., [@B41]). Ventricular arrhythmias therefore, are unlikely to cause suspicion of ARVC in Brugada syndrome patients.

Imaging studies have revealed moderate structural abnormalities in Brugada syndrome patients despite exclusion of structural heart disease in the process of diagnosing the Brugada syndrome. Magnetic resonance imaging (MRI) in 20 Brugada syndrome patients demonstrated a larger right ventricular outflow tract area compared with control subjects and a high intramyocardial T1 signal suggestive for fatty infiltration in 4 patients (Papavassiliu et al., [@B60]). A more elaborate MRI study also identified right ventricular wall motion abnormalities and increased right ventricular end-systolic and inflow tract diameters in Brugada syndrome patients (Catalano et al., [@B14]). The structural and functional abnormalities on MRI appear to be more outspoken in patients with spontaneous than a drug-induced Brugada ECG pattern (Papavassiliu et al., [@B59]). Right ventricular angiography is rarely used in the work-up of Brugada syndrome patients, however microaneurysms during angiography were identified by Frustaci et al. ([@B25]) in 7 out of 18 patients undergoing RV endocardial biopsy.

Thus far, three studies systematically analyzed endocardial biopsies of Brugada syndrome patients (Frustaci et al., [@B25]; Zumhagen et al., [@B83]; Ohkubo et al., [@B57]). These studies produced varied findings. In a series of septal right and left ventricular biopsies 1 out of 18 patient was consistent with ARVC in the series by Frustaci et al. ([@B25]) The biopsies in other patients demonstrated lymphocytic infiltration in 14 and hypertrophy and diffuse vacuolization in 3 patients. No microaneurysms during right ventricular angiography or signs of myocarditis in endocardial biopsies from multiple RV locations were detected by Zumhagen et al. ([@B83]) However, mild myocardial abnormalities were detected in endocardial biopsies of most patients. These changes consisted of hypertrophy, fatty replacement, or fibrosis. The combination of fatty replacement and fibrosis as required for the diagnosis of ARVC, was present in 2 patients (Zumhagen et al., [@B83]). A biopsy series from Japan, 5 out of 25 patients moderate to severe fatty replacement was present in RV septal biopsies which were accompanied by fibrosis in 4 patients (Ohkubo et al., [@B57]).

Mutations in genes associated with ARVC appear to be rare in Brugada syndrome patients. No mutations in the gene encoding plakophilin-2, the gene most commonly involved in ARVC (Kapplinger et al., [@B36]), could be identified in screening of 38 Brugada syndrome patients in whom *SCN5A* were previously excluded (Koopmann et al., [@B40]).

Potential Causes of the Overlapping Features between Brugada Syndrome and ARVC Patients
=======================================================================================

Arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome show an overlap: (1) the Brugada ECG pattern and the associated polymorphic VTs are present or can be provoked by sodium channel blockers in a subgroup of ARVC patients and (2) three of the diagnostic categories of the Task Force Criteria of ARVC namely conduction abnormalities, wall motion abnormalities and histology of the right ventricle are present in Brugada syndrome patients. The question arises at what level these conditions interact.

Firstly, these syndromes could interact at a genetic level. Mutations in genes associated with ARVC patients could cause electrophysiological changes that facilitate the pathophysiological mechanism of the Brugada syndrome. Support for this hypothesis can be found in cellular models of reduced mechanical coupling of cardiomyocytes. The adhering junctions, cardiac sodium channels and gap-junctions, responsible for the electrical coupling between cardiomyocytes, colocalize at the intercalated disk. Mechanical stability of the intercalated disk is thought to be important for the function of cardiac sodium channels and gap-junctions (Delmar and McKenna, [@B21]). In cultured neonatal rat ventricular myocytes a reduction in the expression of plakophilin-2 is associated with a reduction in the *I*~Na~ (Sato et al., [@B73]) and electrical coupling (Oxford et al., [@B58]). However, no indications of altered *I*~Na~ characteristics could be found recently in a murine model of heterozygous desmoplakin knockout (Gomes et al., [@B28]). Reversely, loss-of-function in *SCN5A* associated with Brugada syndrome may predispose patients to develop structural myocardial derangements as observed in ARVC. Support for such an hypothesis can be found in heterozygous *SCN5A*-knockout mice which develop cardiac fibrosis upon aging (Royer et al., [@B71]). The mechanism by which the reduced expression of the cardiac sodium channel causes fibrosis is currently unknown. Toxicity studies with the sodium channel blocker flecainide question whether the observed cardiac fibrosis is the direct result of reduced *I*~Na~. Long-term treatment with flecainide did not result in cardiac fibrosis in mice and was even associated with a reduced prevalence of cardiac fibrosis in rats (Case et al., [@B13]). It is therefore uncertain whether these observations in cellular or mouse models can be extrapolated to man. In case these mechanisms are operational in man, interaction at a genetic level is unlikely to fully account for the overlap between ARVC and Brugada syndrome. As indicated above, no mutations in the gene encoding plakophilin-2 could be identified in screening of Brugada syndrome patients (Koopmann et al., [@B40]) and a mutation in *SCN5A* could be identified in only 1 out of 17 ARVC patients with a drug-induced Brugada ECG pattern (Peters, [@B62]). Furthermore, structural abnormalities in Brugada syndrome patients could also be identified in the absence of *SCN5A* mutations (Frustaci et al., [@B25]; Zumhagen et al., [@B83]).

Secondly, the electrophysiological mechanism of the Brugada syndrome could cause structural derangements. Support for this hypothesis can be found in MRI studies. Right ventricular derangements are more outspoken in patients with a spontaneous than those with a drug-induced Brugada ECG pattern (Papavassiliu et al., [@B59]). Patients with a spontaneous Brugada ECG pattern are known to be at increased risk of arrhythmic events (Probst et al., [@B68]). One could therefore also argue that patients with more structural derangements are more severely affected and are more likely to demonstrate a spontaneous Brugada ECG pattern. The fact that sodium channel blockers can provoke the Brugada ECG pattern in some ARVC patients indicate that the electrophysiological mechanism depends on structural derangements and not the other way around (Peters et al., [@B63]).

Thirdly, structural abnormalities could facilitate the development of the Brugada syndrome and that the structural abnormalities inherent to ARVC underlie its overlap with the Brugada syndrome. Thus far, two hypotheses of the pathophysiological mechanism of the Brugada syndrome have been coined. One suggests that that a functional change causes subepicardial abbreviation of action potential ("repolarization hypothesis"; Yan and Antzelevitch, [@B82]), while the other suggest that a structural change in the subepicardium causes conduction abnormalities that lead to activation delay (Coronel et al., [@B17]) or excitation failure (Hoogendijk et al., [@B30]; "depolarization hypothesis") underlies the Brugada syndrome. Both hypotheses account for the modulation of the Brugada syndrome by pharmacological or genetically determined changes in the *I*~Na~ (Miyazaki et al., [@B51]; Chen et al., [@B15]; London et al., [@B44]; Watanabe et al., [@B81]; Hu et al., [@B33]; Kattygnarath et al., [@B38]), *I*~CaL~ (Miyazaki et al., [@B51]; Antzelevitch et al., [@B5]; Burashnikov et al., [@B12]), and transient outward current (*I*~to~; Alings et al., [@B2]; Delpon et al., [@B22]). In the repolarization hypothesis, the balance during phase-1 of the action potential between depolarizing (*I*~Na~ and *I*~CaL~) and repolarizing (*I*~to~) influence the action potential shortening and ST-segment similarly as in Brugada syndrome patients (Yan and Antzelevitch, [@B82]). In the depolarization hypothesis, regional activation delay in structural discontinuous myocardium make conduction sensitive to currents activated after the upstroke of the action potential. Both depolarizing (*I*~Na~ and *I*~CaL~) and repolarizing (*I*~to~) influence the current available for conduction during this phase of the action potential and can modulate the Brugada ECG pattern (Hoogendijk et al., [@B32]).

Testing of these hypothesis has been troublesome because of the epicardial localization of the arrhythmogenic substrate in the Brugada syndrome. Until recently measurements were limited to electrograms recorded through the conus artery which runs over the right ventricular outflow tract (Shimizu et al., [@B76]; Nagase et al., [@B54], [@B55]), monophasic action potentials during open chest surgery (Kurita et al., [@B42]), and a rare explanted heart in the setting of cardiac transplantation (Coronel et al., [@B17]). None of these studies was able to demonstrate ST-segment elevation in local electrograms underlying the Brugada ECG pattern. Recently, Nademanee et al. ([@B53]) did demonstrate ST-segment elevation in unipolar electrograms in an epicardial mapping and ablation study in nine highly symptomatic Brugada syndrome patients. The ST-segment elevation in unipolar electrograms strongly resembled the Brugada EGG pattern. These electrograms were located at low-voltage areas with fractionated activation that markedly exceeding the QRS complex. Ablation at these sites resulted in a marked reduction in arrhythmic events and disappearance of the Brugada ECG pattern in eight out of nine patients. Morphologically identical unipolar electrograms were previously provoked by sodium channel blockade in the explanted heart of a *SCN5A* mutation carrier at sites were the subepicardium was interspersed by fibrous and adipose tissue (Hoogendijk et al., [@B30]). However, no data are available on asymptomatic Brugada syndrome patients and the mechanism underlying the Brugada syndrome is still at debate.

Consequences of the Overlapping Features of ARVC and Brugada Syndrome
=====================================================================

In conclusion, the clinical features of Brugada syndrome and ARVC coincide frequently in patients. The recent publication of the first epicardial electrograms underlying the Brugada ECG pattern support the notion that conduction disturbances in structural discontinuous myocardium underlie the Brugada syndrome (Hoogendijk et al., [@B30]; Nademanee et al., [@B53]). The structural right ventricular abnormalities in ARVC therefore most likely predispose patients to develop the Brugada ECG pattern and the associated ventricular arrhythmias (Hoogendijk et al., [@B31]). The strict exclusion of structural heart disease in the Brugada syndrome as advocated in the 2005 consensus report (Antzelevitch et al., [@B4]) appear arbitrary. These conclusions plead for a broadening of the diagnostic criteria by making a distinction in patients with the Brugada features in the presence and absence (Brugada syndrome) of identifiable underlying structural heart disease.

The treatment of these patients with the Brugada features in the setting of structural heart disease remains challenging. The arrhythmogenic risk in these patients has not been clearly established and may prove to be difficult to determine in the future. First of all, this patients group is heterogeneous and incorporates various underlying cardiac conditions besides ARVC (Corrado et al., [@B19], [@B18]; Tada et al., [@B77]; Peters et al., [@B63]): the Brugada ECG pattern can also occur in the setting of Chagas' disease (Chiale et al., [@B16]; Brito et al., [@B9]). Thus far, prospective data are available of only 17 ARVC patients with drug-induced Brugada ECG (Peters, [@B62]) which is associated with a low arrhythmogenic risk in the setting of Brugada syndrome (Probst et al., [@B68]). Only one monomorphic ventricular was recorded during follow-up (Peters, [@B62]). Secondly, the myocardial condition and arrhythmogenic substrate that facilitates the Brugada features may change over time in patients with and underlying cardiomyopathy. In the ARVC follow-up study by Peters, the reproducibility of drug-induced Brugada ECG pattern was four out of eight (Peters, [@B62]). Until the arrhythmogenic risk in patients with the Brugada ECG pattern in the setting of structural heart disease has been assessed, it appears reasonable to avoid or treat known triggers arrhythmias in Brugada syndrome patients such as certain pharmacological agents (Postema et al., [@B67]) and fever (Amin et al., [@B3]).
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